This site is intended for healthcare professionals
News

MHRA approves Bylvay for progressive familial intrahepatic cholestasis.

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
Albireo Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC).
Condition: Progressive Familial Intrahepatic Cholestasis
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest